1. Home
  2. ONVO

as 11-15-2024 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 7.2M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 102.4K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.97 EPS Growth: N/A
52 Week Low/High: $0.32 - $1.74 Next Earning Date: 11-26-2024
Revenue: $103,000 Revenue Growth: -72.01%
Revenue Growth (this year): 59.08% Revenue Growth (next year): 18.24%

ONVO Daily Stock ML Predictions

Share on Social Networks: